Journal
CLINICAL MICROBIOLOGY AND INFECTION
Volume 14, Issue 2, Pages 183-186Publisher
BLACKWELL PUBLISHING
DOI: 10.1111/j.1469-0691.2007.01891.x
Keywords
antagonist treatment; mortality rate; Mycobacterium tuberculosis; tuberculosis; tumour necrosis factor (TNF)-alpha
Categories
Ask authors/readers for more resources
This study investigated the long-term outcome of patients with tuberculosis (TB) as a complication of tumour necrosis factor (TNF)-alpha blocker therapy. All TB cases (n = 21) complicating TNF-alpha blocker therapy from French university hospitals were collated between January 2000 and September 2002. Outcome was assessed via a postal questionnaire during September 2005. The mortality rate after 4 years was 4.8%, and one patient had relapsed and six (29%) patients had recommenced TNF-alpha antagonist treatment, after appropriate anti-TB therapy, without reactivation. These data support the concept that TNF-alpha antagonists can be restarted in TB patients provided that adequate anti-TB treatment has been completed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available